These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 2884410)

  • 21. Cellular and humoral immune responses to a recombinant P. falciparum CS protein in sporozoite-immunized rodents and human volunteers.
    Nardin EH; Nussenzweig RS; Altszuler R; Herrington D; Levine M; Murphy J; Davis J; Bathurst I; Barr P; Romero P
    Bull World Health Organ; 1990; 68 Suppl(Suppl):85-7. PubMed ID: 2094595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sporozoite malaria vaccine. Where do we stand?
    Nussenzweig V; Nussenzweig S
    Ann Parasitol Hum Comp; 1990; 65 Suppl 1():49-52. PubMed ID: 1702271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction of Malaysian sera with Plasmodium vivax sporozoite antigen.
    Lee M; Davis DR; Ballou WR; Folena-Wasserman G; Lewis GE
    Am J Trop Med Hyg; 1988 Dec; 39(6):535-9. PubMed ID: 3061309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A model for Plasmodium falciparum sporozoite challenge and very early therapy of parasitaemia for efficacy studies of sporozoite vaccines.
    Herrington DA; Clyde DF; Murphy JR; Baqar S; Levine MM; do Rosario V; Hollingdale MR
    Trop Geogr Med; 1988 Apr; 40(2):124-7. PubMed ID: 3043855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli.
    Wirtz RA; Ballou WR; Schneider I; Chedid L; Gross MJ; Young JF; Hollingdale M; Diggs CL; Hockmeyer WT
    Exp Parasitol; 1987 Apr; 63(2):166-72. PubMed ID: 3552712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
    Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
    Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human lymphocyte proliferative response to a sporozoite T cell epitope correlates with resistance to falciparum malaria.
    Hoffman SL; Oster CN; Mason C; Beier JC; Sherwood JA; Ballou WR; Mugambi M; Chulay JD
    J Immunol; 1989 Feb; 142(4):1299-303. PubMed ID: 2464643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Field evaluation of an enzyme-linked immunosorbent assay (ELISA) for Plasmodium falciparum sporozoite detection in anopheline mosquitoes from Kenya.
    Beier JC; Perkins PV; Wirtz RA; Whitmire RE; Mugambi M; Hockmeyer WT
    Am J Trop Med Hyg; 1987 May; 36(3):459-68. PubMed ID: 3555134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2.
    Wizel B; Houghten RA; Parker KC; Coligan JE; Church P; Gordon DM; Ballou WR; Hoffman SL
    J Exp Med; 1995 Nov; 182(5):1435-45. PubMed ID: 7595214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a sporozoite malaria vaccine.
    Nussenzweig V; Nussenzweig RS
    Am J Trop Med Hyg; 1986 Jul; 35(4):678-88. PubMed ID: 2425647
    [No Abstract]   [Full Text] [Related]  

  • 31. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.
    Gordon DM; McGovern TW; Krzych U; Cohen JC; Schneider I; LaChance R; Heppner DG; Yuan G; Hollingdale M; Slaoui M
    J Infect Dis; 1995 Jun; 171(6):1576-85. PubMed ID: 7769295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recognition of different domains of the Plasmodium falciparum CS protein by the sera of naturally infected individuals compared with those of sporozoite-immunized volunteers.
    Calle JM; Nardin EH; Clavijo P; Boudin C; Stüber D; Takacs B; Nussenzweig RS; Cochrane AH
    J Immunol; 1992 Oct; 149(8):2695-701. PubMed ID: 1401909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent efforts in the development of a sporozoite vaccine against human malaria.
    Hockmeyer WT; Dame JB
    Adv Exp Med Biol; 1985; 185():233-45. PubMed ID: 3907309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human malaria sporozoite antigen.
    Alving CR; Richards RL; Moss J; Alving LI; Clements JD; Shiba T; Kotani S; Wirtz RA; Hockmeyer WT
    Vaccine; 1986 Sep; 4(3):166-72. PubMed ID: 3532603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T cell responses to repeat and non-repeat regions of the circumsporozoite protein detected in volunteers immunized with Plasmodium falciparum sporozoites.
    Nardin E; Munesinghe YD; Moreno A; Clavijo P; Calle MC; Edelman R; Davis J; Herrington D; Nussenzweig RS
    Mem Inst Oswaldo Cruz; 1992; 87 Suppl 3():223-7. PubMed ID: 1364202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasmodium vivax: a monoclonal antibody recognizes a circumsporozoite protein precursor on the sporozoite surface.
    Gonzalez-Ceron L; Rodriguez MH; Wirtz RA; Sina BJ; Palomeque OL; Nettel JA; Tsutsumi V
    Exp Parasitol; 1998 Nov; 90(3):203-11. PubMed ID: 9806864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunization of Saimiri sciureus boliviensis with recombinant vaccines based on the circumsporozoite protein of Plasmodium vivax.
    Collins WE; Nussenzweig RS; Ballou WR; Ruebush TK; Nardin EH; Chulay JD; Majarian WR; Young JF; Wasserman GF; Bathurst I
    Am J Trop Med Hyg; 1989 May; 40(5):455-64. PubMed ID: 2658634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
    Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
    PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of 5.1-[NANP]19, a recombinant Plasmodium falciparum vaccine candidate, in adults.
    Stürchler D; Just M; Berger R; Reber-Liske R; Matile H; Etlinger H; Takacs B; Rudin C; Fernex M
    Trop Geogr Med; 1992 Jan; 44(1-2):9-14. PubMed ID: 1496731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of human circumsporozoite antibodies in Plasmodium-infected Anopheles (Diptera: Culicidae).
    Beier JC; Oster CN; Koros JK; Onyango FK; Githeko AK; Rowton E; Koech DK; Roberts CR
    J Med Entomol; 1989 Nov; 26(6):547-53. PubMed ID: 2685310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.